Drugs / AZD4512
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07109219 | Nov 2025 → Apr 2028 expected | B-cell acute lymphoblastic leukemia | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07123454 | Sep 2025 → Mar 2028 expected | B-cell non-Hodgkin lymphoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07123454 ↗ |
| Route | Intravenous | “Patients will receive AZD4512 as monotherapy via intravenous infusion.” NCT07109219 ↗ |